Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients

American Journal of Hematology

Volumn 85, Issue 3, 2010, Pages 171-173

  Thompson, Carrie A ^a   Kyle, Robert ^a   Gertz, Morie ^a   Heit, John ^a   Pruthi, Rajiv ^a   Pardanani, Animesh ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; BLOOD CLOTTING FACTOR 10 DEFICIENCY; CENTRAL VENOUS CATHETERIZATION; DEATH; FEMALE; HEMATOMA; HUMAN; INVASIVE PROCEDURE; LIGHT CHAIN AMYLOIDOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; THROMBOSIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; AMYLOID; AMYLOIDOSIS; CATHETERIZATION, CENTRAL VENOUS; FACTOR X DEFICIENCY; FEMALE; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE HEMORRHAGE; PUNCTURES; RETROSPECTIVE STUDIES; RISK; THROMBOSIS;

EID: 77249130849     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21603     Document Type: Article

References (21)

1. Mumford AD, O'Donnell J, Gillmore JD, et al. Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. Br J Haematol 2000;110:454-460.
2. Halligan CS, Lacy MQ, Vincent Rajkumar S, et al. Natural history of thromboembolism in AL amyloidosis. Amyloid 2006;13:31-36.
3. Gastineau DA, Gertz MA, Daniels TM, et al. Inhibitor of the thrombin time in systemic amyloidosis: A common coagulation abnormality. Blood 1991;77:2637-2640.
4. Choufani EB, Sanchorawala V, Ernst T, et al. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood 2001;97:1885-1887.
5. Furie B, Greene E, Furie BC. Syndrome of acquired factor X deficiency and systemic amyloidosis in vivo studies of the metabolic fate of factor X. N Engl J Med 1977;297:81-85.
6. Furie B, Voo L, McAdam KP, Furie BC. Mechanism of factor X deficiency in systemic amyloidosis. N Engl J Med 1981;304:827-830.
7. Barker B, Altuntas F, Paranjape G, Sarode R. Presurgical plasma exchange is ineffective in correcting amyloid associated factor X deficiency. J Clin Apheresis 2004;19:208-210.
8. Greipp PR, Kyle RA, Bowie EJ. Factor-X deficiency in amyloidosis: A critical review. Am J Hematol 1981;11:443-450.
9. Greipp PR, Kyle RA, Bowie EJ. Factor X deficiency in primary amyloidosis: Resolution after splenectomy. N Engl J Med 1979;301:1050-1051.
10. Boggio L, Green D. Recombinant human factor VIIa in the management of amyloid-associated factor X deficiency. Br J Haematol 2001;112:1074-1075.
11. Takabe K, Holman PR, Herbst KD, et al. Successful perioperative management of factor X deficiency associated with primary amyloidosis. J Gastrointest Surg 2004;8:358-362.
12. Ma JF, Coutre SE, Curet MJ, Brooks JD. Refractory hematuria from amyloidosis successfully treated by splenectomy. Urology 2006;67:1085.e13-5.
13. Kyle RA, Gertz MA. Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-59.
14. Domm JA, Hudson MG, Janco RL. Complications of central venous access devices in paediatric haemophilia patients. Haemophilia 2003;9:50-56.
15. Titapiwatanakun R, Moir C, Pruthi R, et al. Central venous access devices for paediatric patients with haemophilia: A single-institution experience. Haemophilia 2009;15:168-174.
16. Parlak M, Sancak T, Arat M, et al. Tunneled catheters placed in bone marrow transplant patients: Radiological and clinical follow-up results. Diagn Interv Radiol 2006;12:190-194.
17. O'Connell KA, Wood JJ, Wise RP, et al. Thromboembolic Adverse Events After Use of Recombinant Human Coagulation Factor VIIa. JAMA 2006;295:293-298.
18. Green D. Complications associated with the treatment of haemophiliacs with inhibitors. Haemophilia 1999;5 (Suppl 3):11-17.
19. United Kingdom Haemophilia Centre Doctors' Organisation. Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 2003;9:1-23.
20. Batorova A, Martinowitz U. Continuous infusion of coagulation factors. Haemophilia 2002;8:170-177.
21. Ludlam CA, Smith MP, Morfini M, et al. A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: A pharmacokinetic and efficacy evaluation. Br J Haematol 2003;120:808-813.